Review




Structured Review

Purdue Pharma controlled-release tablet ms contin
Controlled Release Tablet Ms Contin, supplied by Purdue Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ms+contin+tablets/sustained+acting+morphine+ms+contin/pm25244248-230-3-7
Average 90 stars, based on 1 article reviews
controlled-release tablet ms contin - by Bioz Stars, 2026-11
90/100 stars

Images

Related Articles

Capsules:

Article Title: The drug crisis and the living arrangements of children.
Article Snippet: There are two important things to note about the exception, morphine: (1) because all drugs are in the same units, the growth is negligible relative to the growth seen for oxycodone, and (2) Purdue Pharma was also actively promoting their continuous-release morphine drug, MS Contin.

Article Title: Patients with chronic pain and dysphagia (CPD): unmet medical needs and pharmacologic treatment options.
Article Snippet: Background: For properly selected patients experiencing chronic pain, extended-release opioid formulations may represent an appropriate pain management choice.. For the many adults, elderly, and children who have medical conditions that make swallowing solid, oral-dose formulations difficult (dysphagia) or painful (odynophagia), this option may be limited.. The combination of chronic pain with dysphagia (CPD) presents a challenge to physicians and patients alike when oral opioid analgesia is needed to control pain, but patients are unable to swallow solid, oral dosage forms.

Article Title: Opioids compared to placebo or other treatments for chronic low‐back pain
Article Snippet: Risk of bias Bias Authors' judgement Support for judgement Random sequence generation (selection bias) Unclear risk "Patients were randomly assigned to receive either sustained acting morphine (15 mg MS‐Contin; Purdue Pharma, Stamford, CT) or weight‐matched placebo capsules".

Article Title: Opioids compared to placebo or other treatments for chronic low‐back pain
Article Snippet: Random sequence generation (selection bias) , Unclear risk , "Patients were randomly assigned to receive either sustained acting morphine (15 mg MS‐Contin; Purdue Pharma, Stamford, CT) or weight‐matched placebo capsules". There was no description of the method of randomization..

Article Title: Opioid analgesics for nociceptive cancer pain: A comprehensive review.
Article Snippet: See the T erm s and C onditions (https://onlinelibrary.w iley.com /term s-and-conditions) on W iley O nline L ibrary for rules of use; O A articles are governed by the applicable C reative C om m ons L icense T A B L E 2 (Continued) Opioid þ regimen Level of evidence Placebo‐ controlled trials, no. (total no.) Background cancer pain type Results group (82.5 MME) compared with 3.0 or 13.5 MME in the morphine sulfate sustained‐release (Kapanol; Mayne Pharma) or morphine sulfate controlled‐ release (MS Contin; Purdue Pharma) groups (Broomhead 199747).

Sequencing:

Article Title: The drug crisis and the living arrangements of children.
Article Snippet: There are two important things to note about the exception, morphine: (1) because all drugs are in the same units, the growth is negligible relative to the growth seen for oxycodone, and (2) Purdue Pharma was also actively promoting their continuous-release morphine drug, MS Contin.

Article Title: Patients with chronic pain and dysphagia (CPD): unmet medical needs and pharmacologic treatment options.
Article Snippet: Background: For properly selected patients experiencing chronic pain, extended-release opioid formulations may represent an appropriate pain management choice.. For the many adults, elderly, and children who have medical conditions that make swallowing solid, oral-dose formulations difficult (dysphagia) or painful (odynophagia), this option may be limited.. The combination of chronic pain with dysphagia (CPD) presents a challenge to physicians and patients alike when oral opioid analgesia is needed to control pain, but patients are unable to swallow solid, oral dosage forms.

Article Title: Opioids compared to placebo or other treatments for chronic low‐back pain
Article Snippet: Risk of bias Bias Authors' judgement Support for judgement Random sequence generation (selection bias) Unclear risk "Patients were randomly assigned to receive either sustained acting morphine (15 mg MS‐Contin; Purdue Pharma, Stamford, CT) or weight‐matched placebo capsules".

Article Title: Opioids compared to placebo or other treatments for chronic low‐back pain
Article Snippet: Random sequence generation (selection bias) , Unclear risk , "Patients were randomly assigned to receive either sustained acting morphine (15 mg MS‐Contin; Purdue Pharma, Stamford, CT) or weight‐matched placebo capsules". There was no description of the method of randomization..

Article Title: Opioid analgesics for nociceptive cancer pain: A comprehensive review.
Article Snippet: See the T erm s and C onditions (https://onlinelibrary.w iley.com /term s-and-conditions) on W iley O nline L ibrary for rules of use; O A articles are governed by the applicable C reative C om m ons L icense T A B L E 2 (Continued) Opioid þ regimen Level of evidence Placebo‐ controlled trials, no. (total no.) Background cancer pain type Results group (82.5 MME) compared with 3.0 or 13.5 MME in the morphine sulfate sustained‐release (Kapanol; Mayne Pharma) or morphine sulfate controlled‐ release (MS Contin; Purdue Pharma) groups (Broomhead 199747).

Selection:

Article Title: The drug crisis and the living arrangements of children.
Article Snippet: There are two important things to note about the exception, morphine: (1) because all drugs are in the same units, the growth is negligible relative to the growth seen for oxycodone, and (2) Purdue Pharma was also actively promoting their continuous-release morphine drug, MS Contin.

Article Title: Patients with chronic pain and dysphagia (CPD): unmet medical needs and pharmacologic treatment options.
Article Snippet: Background: For properly selected patients experiencing chronic pain, extended-release opioid formulations may represent an appropriate pain management choice.. For the many adults, elderly, and children who have medical conditions that make swallowing solid, oral-dose formulations difficult (dysphagia) or painful (odynophagia), this option may be limited.. The combination of chronic pain with dysphagia (CPD) presents a challenge to physicians and patients alike when oral opioid analgesia is needed to control pain, but patients are unable to swallow solid, oral dosage forms.

Article Title: Opioids compared to placebo or other treatments for chronic low‐back pain
Article Snippet: Risk of bias Bias Authors' judgement Support for judgement Random sequence generation (selection bias) Unclear risk "Patients were randomly assigned to receive either sustained acting morphine (15 mg MS‐Contin; Purdue Pharma, Stamford, CT) or weight‐matched placebo capsules".

Article Title: Opioids compared to placebo or other treatments for chronic low‐back pain
Article Snippet: Random sequence generation (selection bias) , Unclear risk , "Patients were randomly assigned to receive either sustained acting morphine (15 mg MS‐Contin; Purdue Pharma, Stamford, CT) or weight‐matched placebo capsules". There was no description of the method of randomization..

Article Title: Opioid analgesics for nociceptive cancer pain: A comprehensive review.
Article Snippet: See the T erm s and C onditions (https://onlinelibrary.w iley.com /term s-and-conditions) on W iley O nline L ibrary for rules of use; O A articles are governed by the applicable C reative C om m ons L icense T A B L E 2 (Continued) Opioid þ regimen Level of evidence Placebo‐ controlled trials, no. (total no.) Background cancer pain type Results group (82.5 MME) compared with 3.0 or 13.5 MME in the morphine sulfate sustained‐release (Kapanol; Mayne Pharma) or morphine sulfate controlled‐ release (MS Contin; Purdue Pharma) groups (Broomhead 199747).



Similar Products

90
Purdue Pharma ms contin placebo tablets
Ms Contin Placebo Tablets, supplied by Purdue Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ms+contin+tablets/ms+contin+placebo+tablets/10__1002_slash_14651858__cd001703__pub4-1894-1-8
Average 90 stars, based on 1 article reviews
ms contin placebo tablets - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Mundipharma gmbh ms contin cr tablets
Ms Contin Cr Tablets, supplied by Mundipharma gmbh, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ms+contin+tablets/ms+contin/pmc07971255-12-2-18
Average 90 stars, based on 1 article reviews
ms contin cr tablets - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Purdue Pharma morphine sulfate er tablets (ms contin
Morphine Sulfate Er Tablets (Ms Contin, supplied by Purdue Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ms+contin+tablets/sustained+acting+morphine+ms+contin/pmc05431384-47-22-30
Average 90 stars, based on 1 article reviews
morphine sulfate er tablets (ms contin - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Mundipharma gmbh ms contin tablets
Ms Contin Tablets, supplied by Mundipharma gmbh, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ms+contin+tablets/ms+contin/pm25530068-36-0-7
Average 90 stars, based on 1 article reviews
ms contin tablets - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Purdue Pharma ms contin morphine sulfate controlled-release tablets

Ms Contin Morphine Sulfate Controlled Release Tablets, supplied by Purdue Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ms+contin+tablets/sustained+acting+morphine+ms+contin/pmc10397816-33-5-8
Average 90 stars, based on 1 article reviews
ms contin morphine sulfate controlled-release tablets - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Purdue Pharma controlled-release tablet ms contin

Controlled Release Tablet Ms Contin, supplied by Purdue Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ms+contin+tablets/sustained+acting+morphine+ms+contin/pm25244248-230-3-7
Average 90 stars, based on 1 article reviews
controlled-release tablet ms contin - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Purdue Frederick Company ms contin® tablets

Ms Contin® Tablets, supplied by Purdue Frederick Company, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ms+contin+tablets/ms+contin/us08685994-22-30-39
Average 90 stars, based on 1 article reviews
ms contin® tablets - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Purdue Pharma ms contin® cr tablets

Ms Contin® Cr Tablets, supplied by Purdue Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ms+contin+tablets/ms+contin/pm23745947-102-14-18
Average 90 stars, based on 1 article reviews
ms contin® cr tablets - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Shionogi ms contin tablet

Ms Contin Tablet, supplied by Shionogi, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ms+contin+tablets/ms+contin+tablet/us08512744-23-14-19
Average 90 stars, based on 1 article reviews
ms contin tablet - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Mundipharma gmbh ms contin controlled-release tablet

Ms Contin Controlled Release Tablet, supplied by Mundipharma gmbh, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ms+contin+tablets/ms+contin/pm22841501-87-7-11
Average 90 stars, based on 1 article reviews
ms contin controlled-release tablet - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Journal: Journal of Managed Care & Specialty Pharmacy

Article Title: Opioid Treatment Patterns Following Prescription of Immediate-Release Hydrocodone

doi: 10.18553/jmcp.2016.22.4.358

Figure Lengend Snippet:

Article Snippet: MS Contin , Morphine sulfate controlled-release tablets , Purdue Pharma.

Techniques: Capsules